NKX6-2 and urinary bladder cancer: Notably, it has been described as part of a biomarker panel for early bladder cancer detection in urine [33], and methylome analysis in RCC has suggested that hypermethylation of NKX6-2 is associated with more aggressive RCC, demonstrating shortened overall survival [36].